Our consortium

Our academic partner organisations

The DaMeSa consortium is a point of intersection for skills and expertise in clinical patient care, systemic patient management, scientific study monitoring, proteomic and genomic diagnostics, experience in ePRO data collection, telecardiology, and medical data technology. All these disciplines will dedicate their efforts to the pursuit of scientific and clinical excellence in the project and to the fulfilment of its objectives.

Organisation-chart of DaMeSa-Partners

Organigramm der DaMeSa-Partner

Our partner organisations can look back on a long track record of collaboration in projects and clinical studies in personalised medicine, as part of major European consortia (PersTIgAN, PRIORITY, ProDial, Crit-CoV-U, ImmunDial, CoVTher, EORTC QoL, UPTAKE, eHealthsax), which together hold a cumulative funding volume of over 20 million euro. They are also part of established collaborations with members of our Scientific Advisory Board, who will support the consortium’s scientific activities in disciplines including oncology, infectiology and epidemiology, complementing its existing expertise in reno-cardiovascular medicine. A few facts and figures may serve to visualise the collective scientific impact of these collaborations: The six academics who will lead the work have a cumulative h-index of over 200; our partner scientists in the omics disciplines have more than 1000 publications between them, while the figure for our data science academics is over 200. Altogether, the number of citations for these works is well over 100,000.

How our business and research partners will work together

DaMeSa’s partner organisations from the commercial field, Mosaiques, Arcensus and Philips Medical, will contribute expertise which is crucial to this aspect of multi-omics analysis; the consortium’s work on omics measurement and integrative analysis will involve the advancement of existing and the development of new products in these SME settings, meaning that translation into the commercial arena is built in to the project from the outset. Mosaiques and Arcensus will develop proteomic-genomic measurement products as approved medical devices and incorporate their use into clinical studies which will serve to test them; cost-benefit analyses will follow, after whose successful outcome the products will be able to find paid-for use in routine medical care funded by Germany’s statutory health insurance system (GKV). GKV actors will be involved in ongoing assessment and evaluation of the project’s developments. The products will access the international for-profit market via established sales channels.

The new Health Suite technology created by Philips Medical is the first multimodal biodata platform usable as an IT ecosystem for the advancement of patient-centred data solutions and Internet of Things (IoT) technologies. The company plans to continue developing the solution in line with current needs, with the help of our consortium’s data scientists and working closely with start-up companies, and to bring it to a market-ready state.

A key aspect of our proposed project is the creation of an exemplary interoperability of omics data with the development of innovative medical products with communicative capacity. The establishment of new standards in this regard will act as a magnet for biomedical technology businesses12 that would set up premises around the omics data campus in order to benefit from the standard and develop new communicative devices. Depending on the final location of the planned multi-omics campus, it is likely that Saxony will be able to realise all fiscal revenues these developments generate.